MRI radiomics model for predicting TERT promoter mutation status in glioblastoma

被引:4
|
作者
Chen, Ling [1 ,2 ]
Chen, Runrong [1 ]
Li, Tao [2 ]
Huang, Lizhao [2 ]
Tang, Chuyun [1 ]
Li, Yao [3 ]
Zeng, Zisan [1 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Radiol, Nanning, Guangxi, Peoples R China
[2] Guangxi Med Univ, Liuzhou Workers Hosp, Affiliated Hosp 4, Dept Radiol, Nanning, Guangxi, Peoples R China
[3] Guangxi Med Univ, Liuzhou Workers Hosp, Affiliated Hosp 4, Dept Neurosurg, Nanning, Guangxi, Peoples R China
来源
BRAIN AND BEHAVIOR | 2023年 / 13卷 / 12期
关键词
glioblastoma; magnetic resonance imaging; radiomics; TERT; IDH MUTATION; METHYLATION; FEATURES; GLIOMAS;
D O I
10.1002/brb3.3324
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Background and purposeThe presence of TERT promoter mutations has been associated with worse prognosis and resistance to therapy for patients with glioblastoma (GBM). This study aimed to determine whether the combination model of different feature selections and classification algorithms based on multiparameter MRI can be used to predict TERT subtype in GBM patients.MethodsA total of 143 patients were included in our retrospective study, and 2553 features were obtained. The datasets were randomly divided into training and test sets in a ratio of 7:3. The synthetic minority oversampling technique was used to achieve data balance. The Pearson correlation coefficients were used for dimension reduction. Three feature selections and five classification algorithms were used to model the selected features. Finally, 10-fold cross validation was applied to the training dataset.ResultsA model with eight features generated by recursive feature elimination (RFE) and linear discriminant analysis (LDA) showed the greatest diagnostic performance (area under the curve values for the training, validation, and testing sets: 0.983, 0.964, and 0.926, respectively), followed by relief and random forest (RF), analysis of variance and RF. Furthermore, the relief was the optimal feature selection for separately evaluating those five classification algorithms, and RF was the most preferable algorithm for separately assessing the three feature selectors. ADC entropy was the parameter that made the greatest contribution to the discrimination of TERT mutations.ConclusionsRadiomics model generated by RFE and LDA mainly based on ADC entropy showed good performance in predicting TERT promoter mutations in GBM. Adult glioblastoma (GBM) is the most common and aggressive primary brain tumor, with a high recurrence and mortality rate. The presence of TERT promoter mutations has been associated with poor prognosis and resistance to therapy, making it an important biomarker for personalized treatment strategies. In this study, we investigated the relationship between multiparameter MRI features and TERT mutation status, establishing a radiomics signature for predicting TERT promoter mutation status, and verified its effectiveness in prognostic assessment with GBM patients. image
引用
收藏
页数:11
相关论文
共 50 条
  • [41] MRI radiomics and potential applications to glioblastoma
    Hooper, Grayson W.
    Ginat, Daniel T.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma
    Weller, Michael
    Papachristodoulou, Alexandros
    Hentschel, Bettina
    Gramatzki, Dorothee
    Felsberg, Joerg
    Loeffler, Markus
    Schackert, Gabriele
    Westphal, Manfred
    Tonn, Joerg
    Silginer, Manuela
    von Deimling, Andreas
    Pietsch, Torsten
    Reifenberger, Guido
    Roth, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA
    Silginer, Manuela
    Papachristodolou, Alexandros
    Hentschel, Bettina
    Gramatzki, Dorothee
    Felsberg, Jorg
    Loeffler, Markus
    Schackert, Gabriele
    Westphal, Manfred
    Tonn, Jorg-Christian
    von Deimling, Andreas
    Pietsch, Torsten
    Reifenberger, Guido
    Roth, Patrick
    Weller, Michael
    NEURO-ONCOLOGY, 2018, 20 : 48 - 49
  • [44] Multiparametric MRI radiomics model to predict overall survival in Glioblastoma Multiforme
    Kolozsi, E.
    Powell, J.
    Piazzese, C.
    Thomas, S.
    Staffurth, J.
    Spezi, E.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S847 - S848
  • [45] Nomogram of magnetic resonance imaging (MRI) histogram analysis to predict telomerase reverse transcriptase promoter mutation status in glioblastoma
    Zhang, Bin
    Zhou, Qing
    Xue, Caiqiang
    Ke, Xiaoai
    Zhang, Peng
    Han, Tao
    Deng, Liangna
    Jing, Mengyuan
    Zhou, Junlin
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2024, 14 (07) : 4840 - 4854
  • [46] Comparative Study of TERT Promoter Mutation Status in Urothelial Carcinomas with Divergent Differentiation
    Brown, Noah
    Lew, Madelyn
    Weigelin, Helmut
    Betz, Bryan
    Mehra, Rohit
    LABORATORY INVESTIGATION, 2017, 97 : 216A - 216A
  • [47] Comparative Study of TERT Promoter Mutation Status in Urothelial Carcinomas with Divergent Differentiation
    Brown, Noah
    Lew, Madelyn
    Weigelin, Helmut
    Betz, Bryan
    Mehra, Rohit
    MODERN PATHOLOGY, 2017, 30 : 216A - 216A
  • [48] RE: TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma
    Populo, Helena
    Lopes, Jose Manuel
    Sobrinho-Simoes, Manuel
    Soares, Paula
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (04):
  • [49] TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract
    Wang, Xiaoyan
    Lopez-Beltran, Antonio
    Osunkoya, Adeboye O.
    Wang, Mingsheng
    Zhang, Shaobo
    Davidson, Darrell D.
    Emerson, Robert E.
    Williamson, Sean R.
    Tan, Puay-Hoon
    Kaimakliotis, Hristos Z.
    Baldridge, Lee Ann
    MacLennan, Gregory T.
    Montironi, Rodolfo
    Cheng, Liang
    FUTURE ONCOLOGY, 2017, 13 (08) : 705 - 714
  • [50] TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK?
    Gramatzki, Dorothee
    Felsberg, Joerg
    Hentschel, Bettina
    Wolter, Marietta
    Schackert, Gabriele
    Westphal, Manfred
    Regli, Luca
    Thon, Niklas
    Tatagiba, Marcos
    Wick, Wolfgang
    Schlegel, Uwe
    Krex, Dietmar
    Matschke, Jakob
    Roth, Patrick
    Suresh, Marian
    Kamp, Marcel
    Rushing, Elisabeth
    Pietsch, Torsten
    von Deimling, Andreas
    Sabel, Michael
    Loeffler, Markus
    Weller, Michael
    Reifenberger, Guido
    NEURO-ONCOLOGY, 2020, 22 : 14 - 14